ZDHHC9 and breast cancer: Disruption of PD-L1 palmitoylation by site-specific mutation (C272A) of PD-L1 or knock-down of ZDHHC9 reduces PD-L1 cell surface distribution, sensitizes breast cancer cells to T cell killing, and inhibits tumor growth in vivo.